The company is developing novel gene therapies using the adeno-associated virus (AAV) for the treatment of neurological disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, and Alzheimer's disease.
On February 12, 2014 Voyager Therapeutics closed their series A funding round with $45 million in funding from Third Rock Ventures.
On April 13, 2015 Voyager Therapeutics closed their series B funding round with $60 million in funding from Wellington Management, Partner Fund Management, Fidelity Management and Research Company, Casdin Capital, and Brookside Capital.
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson's Disease and Friedreich's Ataxia
Voyager Therapeutics, Inc.
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson's Disease and Provides Clinical Update
Global News Wire